Equity Profile

DAWN

Day One Biopharmaceuticals, Inc.

Health CareBiotechnology

May5Tue

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EDT

Company Snapshot

Day One Biopharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and helps investors gauge the company's financial health.

$-0.17

Revenue

Revenue figures indicate the company's ability to generate sales, which is crucial for its growth and sustainability.

$54M

Wall Street expectations, options signals, track record, and call prep available with Pro.

DAWN Q1-2026 Earnings Preview

Context

Company Snapshot

Day One Biopharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer. As part of the healthcare sector, it plays a critical role in addressing unmet medical needs and advancing treatment options in oncology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-8.39%

Avg Stock Reaction

-1.23%

Last Quarter Recap

In Q4 2025, Day One Biopharmaceuticals reported an EPS of $-1.04, significantly missing the estimate of $-0.17. The stock reacted positively, increasing by 2.74% the following day despite the earnings miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Day One Biopharmaceuticals to report a loss of $0.17 per share on revenues of $54 million for Q1 2026. The company's recent earnings history shows a tendency to beat EPS estimates, which could influence market sentiment.

Bull Case

If Day One can exceed the EPS estimate and show strong revenue growth, it may signal a turnaround in its financial performance, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it could raise concerns about its long-term viability and lead to a further decline in stock price.

Key Metrics to Watch

EPS

$-0.17

Earnings per share (EPS) is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$54M

Revenue figures indicate the company's ability to generate sales, which is crucial for its growth and sustainability.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide any updates on its pipeline progress and potential upcoming drug approvals?

Investors will closely watch for any news that could indicate future revenue streams and the company's growth trajectory.

How does management plan to address the recent earnings misses and improve profitability?

Understanding the company's strategy for overcoming financial challenges will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Day One to rebound with improved pipeline news, which could drive revenue growth beyond current expectations.

Supporting Evidence

Day One has a history of surprising on the upside, with a 75% beat rate on EPS over the last eight quarters.

The options market is pricing in a larger move than historical averages, suggesting that investors are anticipating significant news.

Key Risk

If pipeline updates indicate strong progress, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's earnings report will be pivotal in determining whether Day One can regain investor confidence after a series of misses.

Bull Confirmed If

A revenue figure exceeding $60 million would strongly support the bull case, indicating robust demand for its products.

Bear Confirmed If

Conversely, if revenue falls below $48 million, it would confirm the bear case and raise concerns about the company's market position.

Pre-Earnings Positioning

Options Market

Implied Move

±12.3%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move of about 12.3% following the earnings announcement, indicating heightened uncertainty among investors.

Options are pricing ±12.3% while DAWN has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

30d HV

2.5%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Day One beats expectations, history suggests the stock could see a positive reaction, typically around a 2.66% increase on the first day.

In-Line / Cautious

An in-line report may lead to muted reactions as investors await further commentary from management.

Miss

If the company misses expectations, the stock could decline, with historical patterns indicating an average drop of around 0.29%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on drug pipeline advancements and timelines for potential approvals.
2Management's strategy for improving financial performance after recent misses.
3Insights into market demand for their current and upcoming products.
4Comments on competitive landscape and how Day One plans to differentiate itself.
5Any changes in guidance or outlook for the rest of the fiscal year.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Day One Biopharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and helps investors gauge the company's financial health.

$-0.17

Revenue

Revenue figures indicate the company's ability to generate sales, which is crucial for its growth and sustainability.

$54M

Wall Street expectations, options signals, track record, and call prep available with Pro.

DAWN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-8.39%

Avg Stock Reaction

-1.23%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Day One can exceed the EPS estimate and show strong revenue growth, it may signal a turnaround in its financial performance, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it could raise concerns about its long-term viability and lead to a further decline in stock price.

Key Metrics to Watch

EPS

$-0.17

Earnings per share (EPS) is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$54M

Revenue figures indicate the company's ability to generate sales, which is crucial for its growth and sustainability.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide any updates on its pipeline progress and potential upcoming drug approvals?

Investors will closely watch for any news that could indicate future revenue streams and the company's growth trajectory.

How does management plan to address the recent earnings misses and improve profitability?

Understanding the company's strategy for overcoming financial challenges will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Day One to rebound with improved pipeline news, which could drive revenue growth beyond current expectations.

Supporting Evidence

Day One has a history of surprising on the upside, with a 75% beat rate on EPS over the last eight quarters.

The options market is pricing in a larger move than historical averages, suggesting that investors are anticipating significant news.

Key Risk

If pipeline updates indicate strong progress, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's earnings report will be pivotal in determining whether Day One can regain investor confidence after a series of misses.

Bull Confirmed If

A revenue figure exceeding $60 million would strongly support the bull case, indicating robust demand for its products.

Bear Confirmed If

Conversely, if revenue falls below $48 million, it would confirm the bear case and raise concerns about the company's market position.

Pre-Earnings Positioning

Options Market

Implied Move

±12.3%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move of about 12.3% following the earnings announcement, indicating heightened uncertainty among investors.

Options are pricing ±12.3% while DAWN has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

30d HV

2.5%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Day One beats expectations, history suggests the stock could see a positive reaction, typically around a 2.66% increase on the first day.

In-Line / Cautious

An in-line report may lead to muted reactions as investors await further commentary from management.

Miss

If the company misses expectations, the stock could decline, with historical patterns indicating an average drop of around 0.29%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on drug pipeline advancements and timelines for potential approvals.
2Management's strategy for improving financial performance after recent misses.
3Insights into market demand for their current and upcoming products.
4Comments on competitive landscape and how Day One plans to differentiate itself.
5Any changes in guidance or outlook for the rest of the fiscal year.